Sanmed Biotech Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2016

Location

Zhuhai Guangdong China

Primary Industry

Biotechnology

About

Based in Zhuhai, China and established in 2016, Sanmed Biotech, a tumor liquid testing technology provider, is co-found by an American biotechnology company Cynvenio and a subsidiary of Livzon Pharmaceutical Group Inc. The company has raised RMB 300 million series B funding China Merchants Capital. The company has two main technology: Liquid Biopsy and MDA TEST for lung cancer. The company has more than 30 technology patents and authorization. The company mainly provides liquid test reagents for major malignant tumors such as lung cancer, breast cancer, liver cancer, etc. The company cooperates with well known hospital at home and abroad.

Current Investors

Shanghai Kangcheng Investment Management, China Merchants Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biotechnology, Diagnostic, Medical & Imaging Laboratories

Website

www.sanmedbio.com

Verticals

HealthTech

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.